

Subject Index

- Advance Randomization 11, 14
- Allocation Concealment 10, 12, 13, 14, 18, 19, 21, 25, 27, 28, 29, 30, 31, 33, 34, 35, 41, 42, 48, 53, 57, 63, 64, 67, 72, 81, 107, 113, 123, 157, 159, 161, 171, 172, 174, 175, 182, 183
- Allocation Discretion 19, 22, 172, 182
- Alternating Design 8, 20, 45
- Attribution 4, 6, 18, 40, 124, 125, 133
- Baseline Covariate Imbalances 17, 18, 24, 35, 41, 42, 43, 44, 45, 48, 50, 51, 52, 53, 57, 63, 65, 66, 67, 69, 70, 71, 75, 76, 78, 79, 85, 94, 95, 96, 98, 100, 123, 124, 126, 127, 128, 129, 130, 131, 134, 144, 148, 149, 157, 158, 159, 160, 162, 163, 173, 178, 182
- Berger-Exner Test of Selection Bias 39, 80, 132, 134, 146, 149, 154, 167, 178, 179, 183
- Berger-Exner Graph 132, 134, 135, 136, 137, 138, 139, 140, 141, 142, 162, 163, 164, 180
- Bernoulli Trial 4
- Biased Coin Design 117
- Big Stick Rule 117
- Burden of Proof 37, 38, 40, 41
- Canadian National Breast Cancer Screening Study 48, 49, 54, 56, 58, 60, 62, 127, 157, 159, 161
- Captopril Prevention Project 53, 159
- Case-Control Studies 6, 7
- Causal Inference 4
- Centralized Telephone System 49, 50
- Chronological Bias 108, 109, 111, 112, 115, 116, 117, 121, 122, 171, 172
- Cluster Randomization 28, 52, 55, 65, 67, 68
- Comprehensive Cohort Follow-up Study 142, 160, 176
- Condition B 112, 113, 114, 115, 116, 119, 121, 122
- Condition F 113, 116
- Condition T 112, 113, 116, 121, 122
- Condition V 114, 116
- Confounding 5, 7, 105, 108, 123, 131, 133, 134, 145, 158, 161
- Consumer Randomization 9, 10, 19
- Conventional Randomization 23, 25, 27
- Convergent Strategy 89, 90, 91, 92, 93, 94, 102, 115
- Coronary Artery Surgery Study (CASS) 50, 143
- Covariate 6, 7, 9, 11, 14, 17, 22, 23, 100, 101, 111, 123, 124, 126, 127, 128, 129, 130, 131, 132, 134, 143, 144, 145, 148, 149, 150, 153, 154, 158, 160, 162, 163, 164, 165, 166,

204 *Subject Index*

- Covariate (*Continued*)
 172, 173, 174, 175, 178, 179, 180,
 181, 183
- Deferred Enrollment 29, 143, 150,
 182
- Depth of Statistical Significance 76, 77,
 78, 79, 80
- Deterministic Allocations 86, 87, 88,
 89, 90, 91, 92, 93, 94, 112, 113,
 114, 115, 119, 122, 162
- Dictated Allocation 20, 23
- Directional Strategy 91, 92, 93, 94
- Edinburgh Breast Cancer Trial 52, 53,
 54, 56, 58, 60, 62
- Enrollment Discretion 12, 21, 30,
 130
- Etanercept for Juvenile Rheumatoid
 Arthritis 51
- Exchangeability 4, 7
- External Validity 18, 164
- First-Order Residual Selection Bias 14
 Forcing 20
- Goteborg Mammography Trial 53, 54,
 56, 58, 60, 62
- Heart Outcomes Prevention Evaluation
 (HOPE) Study 79, 158
- Heparin for Myocardial Infarction 43
- HIP Mammography Trial 53, 54, 56,
 58, 60, 62
- Historical Controls 5, 7
- Hypertension Detection and Follow-up
 Program 63
- Intent-to-Randomize 160, 180, 183
- Intent-to-Treat 62, 160
- Internal Validity 14, 18
- Ivanova-Barrier-Berger (IBB) Detection
 Method 145, 146, 147
- Ivanova-Barrier-Berger (IBB)
 Correction Method 165
- Lifestyle Heart Trial 50
- Losartan Intervention for Endpoint
 Reduction in Hypertension (LIFE)
 Study 78
- Masking 12, 13, 18, 21, 25, 26, 27, 28,
 29, 39, 41, 42, 81, 107, 108, 111,
 113, 121, 133, 134, 161, 162, 169,
 171, 172, 174, 175, 177, 182, 183
- Maximal Tolerated Imbalance (MTI)
 112, 115, 116, 117, 118, 119, 121,
 122, 172, 174
- Matching 6, 7, 8
- Maximal Procedure 101, 102, 110,
 115, 116, 117, 118, 119, 120, 121,
 122, 174, 175
- Minimization 8, 23, 24, 28
- Mistaken Allocation 43, 52, 64, 75, 77,
 143
- Norwegian Timolol Trial 75, 76, 77,
 158
- Null Hypothesis 4, 17, 24, 37, 46, 72,
 124, 125, 146, 147, 167, 168
- Open-Label Study 72
- Oxytocin for Induction of Labor 45
- Pascal Triangles 119
- Phase II Studies 5
- P-value 4, 8, 9, 45, 46, 50, 51, 53, 61,
 63, 64, 65, 66, 67, 69, 70, 71, 72,
 74, 76, 77, 78, 79, 80, 85, 125, 126,
 128, 129, 147, 149, 150, 152, 159,
 161
- Potential Outcomes 4, 30, 85, 105,
 106, 129, 147, 165, 172
- Predictable Allocations 14, 21, 28, 29,
 30, 35, 86, 87, 88, 89, 90, 91, 92,
 93, 94, 95, 109, 111, 112, 113, 114,
 115, 120, 161, 162
- Primary Covariate 124, 128, 154
- Random Allocation Rule 30, 122
- Random Walk 111, 112, 121

Subject Index 205

- Randomizable 50, 51, 143, 144, 160, 175, 176, 178, 179
- Randomization as the Basis for Inference 4, 8, 9
- Randomized Blocks 19, 23, 30, 45, 51, 52, 63, 80, 81, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 100, 101, 102, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 131, 135, 137, 138, 139, 140, 141, 142, 143, 145, 162, 163, 165, 166, 167, 174, 175, 177, 182
- Randomized Response 176, 177, 178
- Regression to the Mean 127
- Replacement Randomization 109
- Restricted Randomization 30, 72, 83, 86, 108, 109, 111, 113, 115, 116, 117, 119, 120, 122, 124, 132, 161, 177, 182, 183
- Reverse Propensity Score (RPS) 124, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 147, 148, 149, 150, 154, 159, 162, 163, 164, 169, 180, 181
- RSV Immune Globulin for Respiratory Syncytial Virus 47
- Runaway Youth Study 65, 66
- Run-in Period 26, 51, 174, 175, 176, 178
- Screening Log 130, 142, 143, 145, 149, 150, 154
- Sealed Envelopes 43, 49, 50, 53, 63, 64, 78, 161, 179
- Second-Order Residual Selection Bias 14
- Selection Covariate 100, 124, 129, 130, 131, 132, 149, 153, 173, 179, 183
- Stratification 20, 44, 51, 75, 81, 106, 107, 111, 133, 134, 135, 136, 137, 138, 139, 143, 149, 150, 160, 174, 182
- Talc for Pleural Effusions 44
- Third-Order Residual Selection Bias 14, 124, 126, 127, 128, 129, 130, 132, 133, 134, 143, 145, 149, 150, 152, 153, 154, 155
- Time Trends 5, 108, 111
- Tonsillectomy for Throat Infections 45
- Type I Error 17, 40, 76, 85, 100, 101, 102, 115, 119, 120, 125, 147, 167, 168
- Type II Error 40
- University Group Diabetes Program 43
- Unmasked 20, 21, 26, 27, 41, 42, 45, 47, 48, 50, 51, 52, 74, 80, 107, 108, 109, 111, 121, 122, 133, 134, 161, 165, 169, 178, 182
- Unmeasured Latent Covariate 7, 11, 17, 123, 124, 129, 131, 134, 153, 158, 160, 166
- Unrestricted Randomization 29, 108, 112, 122, 132, 171
- Urn Randomization 22
- Variative Induction 173
- Varied Block Sizes 101, 102, 111, 113, 114, 115, 116, 119, 120
- Western Washington Intracoronary Streptokinase Trial 46

